Monday, September 15, 2025 9/15/2025

Gpr182-mediated calcium mobilization is required for definitive hematopoiesis

Award Number: F31HL160183
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 09/01/2021
PERIOD OF PERFORMANCE END DATE: 08/31/2024

Group Awards By:

View Award Description

Gpr182-mediated calcium mobilization is required for definitive hematopoiesis - Abstract Hematopoietic stem cells (HSCs) are self-renewing cells that produce all major blood cell lineages during an individual’s lifetime. During embryonic specification of HSCs, axial vasculature must be appropriately patterned; vascular endothelial cells of the embryonic aorta can be broadly categorized into hemogenic endothelium (HE) and non-hemogenic endothelium. HSCs transdifferentiate specifically from HE and enter circulation. It has long been understood that proper tissue patterning and transcriptional regulation are required for adequate specification and production of HSCs. More recently, it has become clear that cell populations surrounding the sites of HSC development—known as the HSC microenvironment—provide inductive signaling cues that are required for HSC specification. Signaling molecules established in HSC specification, such as Wingless (Wnt) and Hedgehog (Hh), activate G protein-coupled receptor (GPCR)-driven signaling pathways in endothelial cells. Our lab has demonstrated that Gpr182, an endothelial GPCR without a currently known ligand, regulates intracellular Ca2+ mobilization during the time of HSC specification. Transient loss of Gpr182 leads to a reduction in HSC precursors. These data suggest that a Gpr182-induced increase in calcium levels may be required for HSC specification. Our lab has also shown that pharmacological inhibition of the calcium sensor and effector proteins calmodulin and calcineurin disrupts HSC specification. The nuclear factor of activated T cells (NFAT) family of transcription factors act downstream of calcineurin. Several NFAT family members are expressed at the right time and place to potentially influence HSC specification in the zebrafish model. However, it is unknown whether or how these transcription factors HSC specification. While in vitro data have shown a connection between Gpr182 expression and NFAT response element activity, no connection between these two molecules has been made in vivo. I hypothesize that Gpr182-mediated activation of the Ca2+-calcineurin-NFAT signaling axis is required for HSC specification. To test this hypothesis, I will first evaluate the role of Gpr182 activity in Ca2+ mobilization and HSC specification by defining that Gpr182 is required for HSC specification, evaluating the effects of gpr182 gene knockout on Ca2+ mobilization, assessing the contribution of Gpr182 candidate co-receptor Ramp2 to endothelial Ca2+ mobilization, and determining if Gpr182 functions cell- autonomously in HSC precursors. Second, I will determine if NFAT transcription factors are required for HSC specification through performing loss-of-function genetic studies with morpholino oligonucleotides, generating stable mutant knockout zebrafish, and assessing the potential for constitutively active NFAT to rescue hematopoietic defects caused by Gpr182 loss-of-function. These studies will advance the field of developmental hematopoiesis by establishing a previously unknown role for Ca2+ mobilization and NFAT activity in HSC specification. These findings will better inform efforts of reprogramming HSCs from induced pluripotent stem cells (iPSCs), which has been a longstanding goal of regenerative medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$6,117 )
2025	2023	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL # 1500	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	3	7/25/2025	NON-COMPETING CONTINUATION	-$6,117
														Subtotal = -$6,117

Issue Date FY: 2023 ( Subtotal = $43,694 )
2023	2023	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	3	8/14/2023	NON-COMPETING CONTINUATION	$43,694
														Subtotal = $43,694

Issue Date FY: 2022 ( Subtotal = $42,752 )
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	001	2	8/19/2022	NON-COMPETING CONTINUATION	$42,752
2022	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	1	8/18/2022	NEW	$0
														Subtotal = $42,752

Issue Date FY: 2021 ( Subtotal = $42,036 )
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Blood Diseases and Resources Research	000	1	8/19/2021	NEW	$42,036
														Subtotal = $42,036

Grand Total All Awards = $122,365

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Gpr182-mediated calcium mobilization is required for definitive hematopoiesis

Award Number: F31HL160183

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 09/01/2021

PERIOD OF PERFORMANCE END DATE: 08/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer